Literature DB >> 22886469

Primary Sjögren's syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia.

Faten Ismail1, Amel Mahmoud, Hisham Abdelhaleem, Amro Mamdoh, M Geneidy, Enas Kamal.   

Abstract

Primary Sjögren's syndrome (PSS) is associated with increased risk of lymphoproliferative malignancy, and B-cell non-Hodgkin lymphoma (B-NHL) is the most frequent type. To evaluate CD4+ T lymphocytes distributions in patients with (PSS) and the association of CD4+ T lymphocytopenia with the development of (B-NHL), this study included 8 (PSS) patients associated with B-NHL (group I), 50 (pSS) patients without B-NHL (group II), and 30 healthy volunteers who served as controls. The frequency of circulating CD4+ and CD8+ T lymphocytes distributions and CD4+/CD8+ T cell ratio was assessed using flow cytometry coulter EPICS-XL and compared between patients groups and controls. There was statistically significant CD4+ T lymphocytopenia in (PSS) patients with B-NHL than those without lymphoma and controls (P = 0.001). Moreover, a significant low CD4+/CD8+ T cell ratio 0.8 in group I than group II and controls (P = 0.001) was found. Significant positive correlations of CD4+ T lymphocytopenia with other risk factors (parotid swelling, vasculitis, rheumatoid factors, low complement, cryoglobulinemia) were detected. CD4+ T lymphocytopenia is associated with B-NHL developed in patients with PSS and can be considered as an important predictor of lymphoma.

Entities:  

Mesh:

Year:  2012        PMID: 22886469     DOI: 10.1007/s00296-012-2464-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  23 in total

1.  Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome.

Authors:  M Voulgarelis; U G Dafni; D A Isenberg; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  1999-08

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  [Lymphoproliferative disorders in Sjögren's syndrome].

Authors:  Monika Prochorec-Sobieszek; Teresa Wagner
Journal:  Otolaryngol Pol       Date:  2005

4.  Correlation of increased susceptibility to apoptosis of CD4+ T cells with lymphocyte activation and activity of disease in patients with primary Sjögren's syndrome.

Authors:  M Zeher; P Szodoray; E Gyimesi; Z Szondy
Journal:  Arthritis Rheum       Date:  1999-08

5.  [Malignant lymphoma associated with primary Sjögren's syndrome].

Authors:  Li Wang; Yan Zhao; Feng-chun Zhang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2010-10-26

6.  [Characteristics of patients with primary Sjögren's syndrome and non-Hodgkin's lymphoma: analysis of 9 cases].

Authors:  Ning Jia; Fu-Lin Tang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2009-10-27

Review 7.  Lymphomas complicating Sjögren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells.

Authors:  X Mariette
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

8.  Prevalence of HCV among Yemeni patients with non-Hodgkin's lymphoma at AI-Thawra teaching hospital.

Authors:  A K Salem
Journal:  Gulf J Oncolog       Date:  2009-01

9.  Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study.

Authors:  Elke Theander; Rolf Manthorpe; Lennart T H Jacobsson
Journal:  Arthritis Rheum       Date:  2004-04

Review 10.  B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.

Authors:  Arne Hansen; Peter E Lipsky; Thomas Dörner
Journal:  Nat Clin Pract Rheumatol       Date:  2007-10
View more
  8 in total

Review 1.  Rheumatology in Egypt: back to the future.

Authors:  Tamer A Gheita; Nahla N Eesa
Journal:  Rheumatol Int       Date:  2018-11-07       Impact factor: 2.631

2.  Clinical Phenotype and Mechanisms of Leukopenia/Neutropenia in Patients with Primary Sjögren's Syndrome.

Authors:  Ioanna E Stergiou; Efstathia E Kapsogeorgou; Athanasios G Tzioufas; Michalis Voulgarelis; Andreas V Goules
Journal:  Mediterr J Rheumatol       Date:  2022-03-31

3.  High salivary soluble L-selectin and interleukin-7 levels in Asian Indian patients with primary Sjögren's syndrome.

Authors:  Jayakanthan Kabeerdoss; Pulukool Sandhya; Santosh Kumar Mandal; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2016-09-12       Impact factor: 2.980

Review 4.  Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Authors:  Maria B Nishishinya; Claudia A Pereda; Santiago Muñoz-Fernández; José M Pego-Reigosa; Iñigo Rúa-Figueroa; José-Luis Andreu; Mónica Fernández-Castro; José Rosas; Estibaliz Loza Santamaría
Journal:  Rheumatol Int       Date:  2014-06-05       Impact factor: 2.631

5.  Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.

Authors:  Lingli Dong; Yu Chen; Yasufumi Masaki; Toshiro Okazaki; Hisanori Umehara
Journal:  Curr Immunol Rev       Date:  2013-02

6.  Procalcitonin as diagnostic marker of infection in solid tumors patients with fever.

Authors:  B Vincenzi; I Fioroni; F Pantano; S Angeletti; G Dicuonzo; A Zoccoli; D Santini; G Tonini
Journal:  Sci Rep       Date:  2016-06-17       Impact factor: 4.379

Review 7.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Authors:  Christine Ménétrier-Caux; Isabelle Ray-Coquard; Jean-Yves Blay; Christophe Caux
Journal:  J Immunother Cancer       Date:  2019-03-28       Impact factor: 13.751

Review 8.  Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.

Authors:  Syed H Jafri; Runhua Shi; Glenn Mills
Journal:  BMC Cancer       Date:  2013-03-27       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.